206 related articles for article (PubMed ID: 23567407)
1. Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET).
Drye LT; Scherer RW; Lanctôt KL; Rosenberg PB; Herrmann N; Bachman D; Mintzer JE;
Am J Geriatr Psychiatry; 2013 Jun; 21(6):549-59. PubMed ID: 23567407
[TBL] [Abstract][Full Text] [Related]
2. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.
Scherer RW; Drye L; Mintzer J; Lanctôt K; Rosenberg P; Herrmann N; Padala P; Brawman-Mintzer O; Burke W; Craft S; Lerner AJ; Levey A; Porsteinsson A; van Dyck CH;
Trials; 2018 Jan; 19(1):46. PubMed ID: 29347996
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.
Rosenberg PB; Lanctôt KL; Drye LT; Herrmann N; Scherer RW; Bachman DL; Mintzer JE; ADMET Investigators
J Clin Psychiatry; 2013 Aug; 74(8):810-6. PubMed ID: 24021498
[TBL] [Abstract][Full Text] [Related]
4. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Mintzer J; Lanctôt KL; Scherer RW; Rosenberg PB; Herrmann N; van Dyck CH; Padala PR; Brawman-Mintzer O; Porsteinsson AP; Lerner AJ; Craft S; Levey AI; Burke W; Perin J; Shade D;
JAMA Neurol; 2021 Nov; 78(11):1324-1332. PubMed ID: 34570180
[TBL] [Abstract][Full Text] [Related]
5. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments.
Lanctôt KL; Scherer RW; Li A; Vieira D; Coulibaly H; Rosenberg PB; Herrmann N; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Burke WJ; Mintzer JE
Am J Geriatr Psychiatry; 2021 Jan; 29(1):81-89. PubMed ID: 32565008
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.
Lanctôt KL; Rivet L; Tumati S; Perin J; Sankhe K; Vieira D; Mintzer J; Rosenberg PB; Shade D; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey AI; Padala KP; Herrmann N
Am J Geriatr Psychiatry; 2023 Dec; 31(12):1077-1087. PubMed ID: 37385898
[TBL] [Abstract][Full Text] [Related]
7. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
Padala PR; Padala KP; Lensing SY; Ramirez D; Monga V; Bopp MM; Roberson PK; Dennis RA; Petty F; Sullivan DH; Burke WJ
Am J Psychiatry; 2018 Feb; 175(2):159-168. PubMed ID: 28945120
[TBL] [Abstract][Full Text] [Related]
8. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).
Zeng L; Perin J; Gross AL; Shade D; Lanctôt KL; Lerner AJ; Mintzer JE; Brawman-Mintzer O; Padala PR; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Herrmann N; Rosenberg PB
Int J Geriatr Psychiatry; 2024 Jun; 39(6):e6108. PubMed ID: 38858522
[TBL] [Abstract][Full Text] [Related]
9. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
Lanctôt KL; Chen C; Mah E; Kiss A; Li A; Shade D; Scherer RW; Vieira D; Coulibaly H; Rosenberg PB; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Burke WJ; Mintzer J; Herrmann N
Int Psychogeriatr; 2023 Nov; 35(11):664-672. PubMed ID: 37066690
[TBL] [Abstract][Full Text] [Related]
10. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.
Lavretsky H; Reinlieb M; St Cyr N; Siddarth P; Ercoli LM; Senturk D
Am J Psychiatry; 2015 Jun; 172(6):561-9. PubMed ID: 25677354
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Management of Apathy in Dementia.
Azhar L; Kusumo RW; Marotta G; Lanctôt KL; Herrmann N
CNS Drugs; 2022 Feb; 36(2):143-165. PubMed ID: 35006557
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Psychostimulants for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Iwata N
Pharmacopsychiatry; 2020 Apr; 53(3):109-114. PubMed ID: 32000270
[TBL] [Abstract][Full Text] [Related]
13. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Ravindran AV; Kennedy SH; O'Donovan MC; Fallu A; Camacho F; Binder CE
J Clin Psychiatry; 2008 Jan; 69(1):87-94. PubMed ID: 18312042
[TBL] [Abstract][Full Text] [Related]
14. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.
Herrmann N; Rothenburg LS; Black SE; Ryan M; Liu BA; Busto UE; Lanctôt KL
J Clin Psychopharmacol; 2008 Jun; 28(3):296-301. PubMed ID: 18480686
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate for apathy and functional status in dementia of the Alzheimer type.
Padala PR; Burke WJ; Shostrom VK; Bhatia SC; Wengel SP; Potter JF; Petty F
Am J Geriatr Psychiatry; 2010 Apr; 18(4):371-4. PubMed ID: 20220576
[TBL] [Abstract][Full Text] [Related]
16. [Apathetic geriatric patient benefits from methylphenidate].
Ter Keurst A; Tuerlings JHAM; Bertholet EA; Wijnen HW
Ned Tijdschr Geneeskd; 2017; 161():D1903. PubMed ID: 28914218
[TBL] [Abstract][Full Text] [Related]
17. Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study.
Clark ED; Perin J; Herrmann N; Brawman-Mintzer O; Lanctôt KL; Lerner AJ; Mintzer J; Padala PR; Rosenberg PB; Sami S; Shade DM; van Dyck CH; Porsteinsson AP;
Alzheimers Dement (N Y); 2023; 9(3):e12403. PubMed ID: 37538343
[TBL] [Abstract][Full Text] [Related]
18. Apathy in Dementia: Systematic Review of Recent Evidence on Pharmacological Treatments.
Harrison F; Aerts L; Brodaty H
Curr Psychiatry Rep; 2016 Nov; 18(11):103. PubMed ID: 27726067
[TBL] [Abstract][Full Text] [Related]
19. Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease.
Andrade C
J Clin Psychiatry; 2022 Feb; 83(1):. PubMed ID: 35120284
[TBL] [Abstract][Full Text] [Related]
20. New pharmacological options for treating advanced Parkinson's disease.
Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
